Showing posts with label psychosis. Show all posts
Showing posts with label psychosis. Show all posts

Tuesday, June 18, 2013

The Treatment of Early Age Mania Study Revisited

The Treatment of Early Age Mania (TEAM) study is not news, and more diligent and timely bloggers have already written about it. However, it is one of the more infuriating outcomes of the whole pediatric bipolar disorder phenomenon; in the last few years, few publications have irked me as much as the ones from this study. Thus, I'd like to chime in as well. 1 Boring Old Man had a lengthy blog post (the sound and the fury...) summarizing the main findings [I added the links]:
The first report shows that these children respond better to Risperdal® than either Lithium or Depakote®. That’s no surprise. They don’t respond to the traditional anti-manic treatments [that suggests to me that they don't have mania]. They do respond to Risperdal®. That’s something we knew before we ever heard of Risperdal® – you can control disruptive behavior with antipsychotic medications. It also showed that the metabolic side effects of Risperdal® were already apparent at only 8 weeks. Notice that there’s no placebo group in this study so we can’t really say that the Lithium or Depakote® responses were clinically significant.

The second report set out to define moderators of response. What it ended up showing was the extremely high overlap between ADHD and the presumed Bipolar Mania and the more ADHD, the greater the likelihood of a response. But there was another moderator of response – site. What in the hell does that mean? To me it suggests that there is bias in making this diagnosis or in measuring the response. I think that says something about the study and the diagnosis, not the afflicted. So in my reading, one thing it doesn’t mean is that Bipolar Disorder has some intrinsic regional difference.
1BOM used the study to illustrate how a fad diagnosis could become mainstream, to the detriment of children and their families, while benefitting pharmaceutical companies and the researchers (such as MGH's Joseph Biederman) they support. It's worth noting, though, that the TEAM study did not include the MGH group and was funded by the NIMH, not by pharma. The first author of the initial publication is Dr. Barbara Geller, and I've written about how her conception of childhood bipolar is different from Wozniak/Biederman's chronically irritable patients, with Dr. Geller trying taking into account more classical manic symptoms such as grandiosity. Thus, I've often wondered "what the hell happened?" when pondering this study.

Fortunately, Dr. Stuart Kaplan, child psychiatrist and author of Your Child Does Not Have Bipolar Disorder, has an excellent series of posts on his Psychology Today blog with additional insights into the TEAM study. In Dr. Kaplan's first post (The World Series of Child Bipolar Disorder), he describes a session from the 2011 AACAP meeting in which TEAM researchers talked about their study:
During the discussion, another nationally known presenter gave a wildly incorrect interpretation of defiance. The presenter claimed that defiant children are psychotic because they have a delusional belief that they can take on the far stronger adult world. Defiant children are not psychotic based on their defiance alone. They are mistaken in their belief that they can overpower the adult world, but this is a mistaken belief not a delusion. If the investigators believe that defiant children are delusional, this may explain how they found the high rates of psychosis in the children they studied (77%).
If defiance in children counts as psychosis, then my partner and I are both psychotic every time we argue, because we each have a false belief that we can convince the other with our arguments. Maybe some of the TEAM investigators would consider this folie à deux?

Dr. Kaplan's second post (Credulity Stretched) highlights the reasons why the children included in the study probably did not have bipolar 1 disorder, given the >90% comorbidity with ADHD, the 99.3% of patients with "daily rapid cycling" moods, and the fact that the average "manic" episode in the study lasted 4.9 years, which is about half the life of the average study participant (mean age 10.1 years). His third post in the series (Location, Location, Location) replicates the table from the second publication showing just how wildly variable the treatment response was at the various sites: "This was not a minor statistical artifact, but was the central finding of the study."

Besides highlighting the incredible (as in, not credible) aspects of the study that Dr. Kaplan already wrote about, I wanted to provide one additional anecdote: Several years ago, one of the renowned lead investigators of the TEAM study gave a talk at another institution. This mood disorder expert claimed that a 3-year-old who masturbates may be exhibiting the hyper-sexuality seen in mania. When audience members pointed out that a 3-year-old masturbating is actually normal behavior, the investigator appeared flabbergasted. Which makes me wonder if they thought 6-year-olds who were repeatedly touching themselves in defiance of parents telling them to stop were having manic episodes with psychosis.

One of the biggest problems in the field today is how biologically-oriented psychiatrists look at behavior in a vacuum without considering developmental, social, or familial factors. This study is one of the most egregious examples, not just of that problem, but also of how researchers at prestigious institutions, backed by NIMH funding, can get even the most ridiculous studies published. If I see a 16-year-old who is truly manic, I'm still going to seriously consider lithium over risperidone, "evidence-base" be damned.

Friday, May 24, 2013

Preventing Transition to Schizophrenia: What Doesn't Work, What Might

One of the reasons I decided to become a child psychiatrist was seeing the devastating effects of schizophrenia in adult patients during medical school, and knowing even then how inadequate the treatments were. I thought that by working with children and adolescents, that someday I might be a part of preventing someone from developing schizophrenia in the first place.

However, during residency, I became more jaded about early intervention in treating "prodromal" symptoms, in large part because the institution where I was training emphasized biological treatments above all else. One professor, who had close ties to multiple pharmaceutical companies, exhorted us to use antipsychotic medications not only for teenagers with odd thinking or behaviors, but also for those with paranoid or schizotypal personalities, despite there not being a damn bit of evidence this would help anything.

When the evidence did start coming in for the use of antipsychotics to prevent transition to schizophrenia, it was not encouraging. From the most recent meta-analysis I could find:
One study compared CBT and risperidone with CBT and placebo. Very low quality evidence within the first six months of treatment suggested no difference in transition to psychosis (risk ratio 1.02 (95% confidence interval 0.15 to 6.94)), which remained at 12 months (1.02 (0.39 to 2.67)). Differences in symptoms of psychosis (total, positive, or negative), depression, and quality of life were not significant. Dropout was similar between groups (1.09 (0.62 to 1.92)), although the evidence was also rated as very low quality.

There was very low quality evidence for the benefits and harms associated with olanzapine, from one study comparing olanzapine with placebo. We saw no difference in transition to psychosis after 12 months (risk ratio 0.44 (95% confidence interval 0.17 to 1.08)). Dropout was similar between groups at 12 months (1.59 (0.88 to 2.88)). For participants taking olanzapine, there was a large effect on weight during the first eight weeks (standardised mean difference 0.81 (0.28 to 1.34)), which remained large at 12 months (1.18 (0.62 to 1.73)). Effects on symptoms of psychosis (total, positive, or negative), depression, and mania were not significant. Data at 24 months were not analysed because fewer than 50% of participants remained.
Thus, I was somewhat skeptical when I saw this on the Twitter yesterday:
Looking at the article (link is to Google's cached version in case you don't have a Medscape login), it described a comprehensive treatment program, implemented community-wide in Portland, Maine, that has "significantly reduced hospitalization rates for initial psychosis by one third." More encouraging was the fact that this program has successfully been replicated at 5 other locations across the country, and according to lead investigator Dr. William McFarlane, rates of conversion to psychosis were "almost identical" between the prodromal group and a control group. What the program actually entails is interesting, and a very different approach to just using an antipsychotic or doing CBT:
As part of the program, at-risk youth, identified with the Structured Interview for the Prodromal Syndromes (SIPS), are offered a comprehensive package of treatment consisting of family education, assertive community treatment, supported education/employment, and low-dose psychotropic medication.
Looking elsewhere, I found more details about the 8 components of the family-aided community treatment (FACT) program in this dissertation. I've truncated each of the bullet points to save space:
  • Community education and outreach: Early Assessment and Support Team/Alliance representatives go into the community to increase awareness about psychosis and to encourage early referrals. These education efforts are offered to a wide range of audiences...
  • Targeted outreach to those in need: Psychosis is often frightening, and even the thought of being diagnosed with such a serious mental health condition may cause a young person to refuse to seek help. Team members meet the youth and family at their level of readiness to form a relationship built on trust. Services are strengths focused and oriented toward issues young people find relevant...
  • Consistent services in the transition from adolescence to adulthood: Services are provided to teens and young adults by the same team...there is no discontinuity of care or caregiver teams just because a person ages out of childhood services.
  • Supported employment/education specialist: This specialist works closely with each program participant...the majority of young people involved with [this program] do not pursue federal disability funding.
  • Psychopharmacology treatment options: When it comes to medications, [the program] emphasizes education and choice. Medications are used cautiously, and close attention is paid to the side effects experienced by the individual.
  • Occupational therapists: These specialists are available to help assess and provide treatment for underlying sensory, cognitive, and functional issues.
  • Family inclusion: Families are viewed as essential partners in the decision making process. Most families participate in evidence-based multifamily psychoeducation treatment focused on increasing knowledge, reducing conflict, and problem solving.
  • Commitment from systems leaders: State and regional leaders work together to develop and realign funding streams, regulations, and workplace policies to best serve individuals in a flexible way, without barriers such as insurance restrictions and gaps between child and adult systems.
Since I was not at the APA, I have no idea how many of the participants in this program were on antipsychotic medications, or whether they could estimate how much the medications actually contributed to the overall outcome. However, I would be willing to bet that the program would work quite well even without the medication component.

Notably, this research is supported not by the NIMH, but by the Robert Wood Johnson Foundation, "the nation's largest philanthropy devoted solely to the public's health." This public health approach is what we need more of in mental health: It takes a village, not just a pill.